(19)
(11) EP 3 004 165 A1

(12)

(43) Date of publication:
13.04.2016 Bulletin 2016/15

(21) Application number: 14732966.8

(22) Date of filing: 28.05.2014
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/IB2014/061786
(87) International publication number:
WO 2014/191936 (04.12.2014 Gazette 2014/49)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 29.05.2013 WO PCT/EP2013/061107

(71) Applicants:
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
    75013 Paris (FR)
  • Assistance Publique Hôpitaux de Paris
    75004 Paris (FR)
  • Université Paris-Est Créteil Val de Marne
    94010 Creteil Cedex (FR)
  • Université Paris Diderot - Paris 7
    75013 Paris (FR)

(72) Inventors:
  • GAULARD, Philippe
    94010 Creteil (FR)
  • ORTONNE, Nicolas
    94010 Creteil (FR)
  • MARIE-CARDINE, Anne
    75010 Paris (FR)
  • BENSUSSAN, Armand
    75475 Paris Cedex 10 (FR)

(74) Representative: Nony 
3, rue de Penthièvre
75008 Paris
75008 Paris (FR)

   


(54) KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS